Methods of treating patients with non‑restructuring chronic critical lower limb ischemia using autologous mesenchymal stem cells
Journal Title: Серце і судини - Year 2019, Vol 0, Issue 1
Abstract
The prevalence of peripheral arteries disease (PAD) ranges from 3 to 10 % in the general population, reaching 15 — 20 % in subjects older than 70 years. PDA affects 27 million people in Europe and the USA. The annual number of cases of critical lower limbs ischemia (CLLI) is from 500 to 1000 new cases per 1 million of the population, with a high level among patients with diabetes. The aim — to improve the results of treatment of patients with CLLI through the development and implementation of methods of autologous transplantation of multipotent mesenchymal stem stromal cells. Materials and methods. The study was conducted on the basis of two clinical centers of the Department of Surgery № 4 of O. O. Bogomolets National Medical University — vascular surgery department of Alexandrovska clinical hospital and clinic of vascular surgery of the Main military hospital Ministry of Defence of Ukraine and had the following design: 1 period — screening, 2nd period — randomization and distribution of patients by treatment groups, 3rd — treatment, 4th — period of observation (3 years). Sampling of subcutaneous fat, cultivation and transplantation of autologous mesenchymal stem cells according to the method proposed by us were carried out to 41 patients. Results and discussion. The frequency of preservation of the lower limbs in patients who were injected with adipocyte stem cells (ASC) was statistically significantly higher than in patients who used other types of therapy, and was 82 % after three years of follow‑up. Conclusions. Therapeutic mechanism of action of ASC, research on of animal models and in patients, mostly lies in the fact that the growth of blood vessels occurs in ischemic lower limb, possibly, through the interaction of local vascular and inflammatory cells and injected ASC. As a result, patients who received this type of therapy had a smaller percentage of performed amputations than patients who did not receive it.
Authors and Affiliations
N. Yu. Litvinova, V. A. Chernyak, O. I. Kefeli‑Yanovska, D. E. Dybenko
Keywords
Related Articles
- EP ID EP561426
- DOI 10.30978/HV2019-1-5
- Views 141
- Downloads 0
Growth differentiation factor 15 — biomarker of poor prognosis in heart failure
Heart failure (HF) is a major factor contributing to premature death in patients with established cardiovascular (CV) disease. There is a large body of evidence that biological markers, primarily natriuretic peptides, ga...
Innovative technologies in vascular surgery
The aim — to search for new diagnostic and therapeutic directions in vascular surgery and study their technologies via experimental and clinical researches. Materials and methods. 1) The temperature during electric weldi...
Prognostic significance of soluble ST2 as predictor of late left ventricular remodeling after ST-segment elevation myocardial infarction
The aim — to study the prognostic value of soluble ST2 regarding the development of pathological left ventricular remodeling (LVR) 6 months after acute ST‑ segment elevation myocardial infarction (STEMI) Materials and m...
Heart failure with preserved ejection fraction: phantom or real independent syndrome with «own face»?
-
Influence of oxygenator treatment with adaptive composition on changes of blood cells during by-pass surgery
The aim — to assess the method of adaptation of the oxygenator’s contact surface based on recipient's blood serum albumin to the patient’s blood cells changes. Materials and methods. On the basis of the Surgical Center...